0001415889-24-027861.txt : 20241127 0001415889-24-027861.hdr.sgml : 20241127 20241127163929 ACCESSION NUMBER: 0001415889-24-027861 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241126 FILED AS OF DATE: 20241127 DATE AS OF CHANGE: 20241127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AKKARAJU SRINIVAS CENTRAL INDEX KEY: 0001253170 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 241511839 MAIL ADDRESS: STREET 1: 565 EVERETT AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Samsara BioCapital GP, LLC CENTRAL INDEX KEY: 0001888829 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 241511841 BUSINESS ADDRESS: STREET 1: 251 CHURCHILL AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 843-5000 MAIL ADDRESS: STREET 1: 251 CHURCHILL AVENUE CITY: PALO ALTO STATE: CA ZIP: 94301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Samsara BioCapital, L.P. CENTRAL INDEX KEY: 0001699737 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 241511840 BUSINESS ADDRESS: STREET 1: 628 MIDDLEFIELD ROAD CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 285-4270 MAIL ADDRESS: STREET 1: 628 MIDDLEFIELD ROAD CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neurogene Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980542593 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 W 24TH STREET STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 BUSINESS PHONE: (877) 237-5020 MAIL ADDRESS: STREET 1: 535 W 24TH STREET STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 FORMER COMPANY: FORMER CONFORMED NAME: Neoleukin Therapeutics, Inc. DATE OF NAME CHANGE: 20190812 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 4 1 form4-11272024_091125.xml X0508 4 2024-11-26 0001404644 Neurogene Inc. NGNE 0001888829 Samsara BioCapital GP, LLC 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 false false true false 0001699737 Samsara BioCapital, L.P. 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 0 0 1 0 0001253170 AKKARAJU SRINIVAS C/O SAMSARA BIOCAPITAL 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 0 0 1 0 0 Common Stock 2024-11-26 4 P 0 20748 24.91 A 1689105 I By Samsara BioCapital, L.P. Common Stock 2024-11-26 4 P 0 10803 26.01 A 1699908 I By Samsara BioCapital, L.P. Common Stock 2024-11-26 4 P 0 15219 26.73 A 1715127 I By Samsara BioCapital, L.P. Common Stock 2024-11-26 4 P 0 2000 27.50 A 1717127 I By Samsara BioCapital, L.P. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 2024-11-27 Samsara BioCapital, L.P., By Samsara BioCapital GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 2024-11-27 /s/ Srinivas Akkaraju 2024-11-27